Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: A 2-year follow-up study

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Roselló Lletí, Esther ^a   Calabuig, Jose R ^a   Morillas, Pedro ^b   Cortés, Raquel ^a   Martínez Dolz, Luis ^a   Almenar, Luis ^a   González Juanatey, Jose R ^c   Lauwers, Catheline ^d   Salvador, Antonio ^a   Portolés, Manuel ^a   Bertomeu, Vicente ^b   Rivera, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^d Hospital San Francesc de Borja   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; CYTOKINE RECEPTOR; PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CARDIOVASCULAR RISK; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; REFERENCE VALUE; REPRODUCIBILITY; AGED; CHEMISTRY; DOPPLER ECHOCARDIOGRAPHY; GENETICS; HYPERTENSION; METABOLISM; METHODOLOGY; MIDDLE AGED; REGRESSION ANALYSIS;

AGED; CYTOKINES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, CYTOKINE; REGRESSION ANALYSIS;

EID: 84857537532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031189     Document Type: Article

References (43)

1. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, et al. (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49: 1733-9.
2. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355: 1126-30.
3. Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, et al. (2011) Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One 6: e14506.
4. Hildebrandt P, Boesen M, Olsen M, Wachtell, Groenning B, (2004) N-terminal pro brain natriuretic peptide in arterial hypertension a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 6: 313-317.
5. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, et al. (2006) Amino-terminal pro-B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47: 874-880.
6. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, et al. (2004) N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 22: 1597-604.
7. Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, et al. (2011) N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension. Hypertension 57: 702-9.
8. Melzi d'Eril G, Tagnochetti T, Nauti A, Klersy C, Papalia A, et al. (2003) Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem 49: 1554-5.
9. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, et al. (2004) High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50: 2052-8.
10. Wu AH, Smith A, Wieczoreck S, Mather JF, Duncan B, et al. (2003) Biological variation for N-terminal pro and B-type natriuretic peptide and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92: 628-31.
11. Frankenstein L, Remppis A, Frankenstein J, Hess G, Zdunek D, et al. (2009) Variability of N-terminal probrain natriuretic peptide in stable chronic heart failure and its relation to changes in clinical variables. Clin Chem 55: 923-9.
12. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR, (2007) Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 28: 177-82.
13. Cortés R, Rivera M, Salvador A, Bertomeu V, de Burgos FG, et al. (2007) Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart 93: 957-62.
14. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, et al. (2005) Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 111: 863-870.
15. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH, (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-72.
16. Roselló-Lletí E, Rivera M, Martínez-Dolz L, González Juanatey JR, Cortés R, et al. (2009) Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens 22: 444-50.
17. Niethammer M, Sieber M, von Haehling S, Anker SD, Munzel T, et al. (2008) Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int J Cardiol 129: 111-7.
18. Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, et al. (2003) N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42: 1909-16.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-72.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-70.
21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-67.
22. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57: 450-8.
23. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writting Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463.
24. Garcia MJ, Thomas JD, Klein AL, (1998) New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 32: 865-875.
25. Taléns-Visconti R, Rivera M, Climent V, Valero R, Martínez-Dolz L, et al. (2006) Maximum longitudinal relaxation velocity of the left ventricle: its clinical value and relationship with NT-proBNP plasma levels in heart failure. Echocardiography 23: 295-302.
26. Bland JM, Altman DG, (1986) Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1: 307-10.
27. Bland JM, Altman DG, (1999) Measuring agreement in method comparison studies. Statistical Methods in Medical Research 8: 135-60.
28. Sievers B, Kirchberg S, Franken U, Puthenveettil BJ, Bakan A, et al. (2005) Visual estimation versus quantitative assessment of left ventricular ejection fraction: a comparison by cardiovascular magnetic resonance imaging. Am Heart J 150: 737-42.
29. Cortés R, Otero MR, Morillas P, Roselló-Lletí E, Grigorian L, et al. (2008) Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels. Am J Hypertens 21: 820-5.
30. Toda K, Sato Y, Hara T, Hijiya K, Kaneko R, et al. (2010) Correlates of NT-proBNP concentration in patients with essential hypertension in absence of congestive heart failure. J Clin Lab Anal 24: 12-6.
31. Harada M, Saito Y, Kuwahara K, Ogawa E, Ishikawa M, et al. (1998) Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol 31 (suppl): S357-9.
32. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, et al. (2004) Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109: 2872-7.
33. de Bold AJ, Bruneau BG, Kuroski de Bold ML, (1996) Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31: 7-18.
34. Isnard R, (2008) NT-BNP/BNP for screening left ventricular hypertrophy in hypertension: what else? Arch Cardiovasc Dis 10: 295-7.
35. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-442.
36. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, et al. (1996) Marked expression plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 28: 1234-1242.
37. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, et al. (1993) Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88: 372-380.
38. Nian M, Lee P, Khaper N, Liu P, (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543-1553.
39. Deten A, Volz HC, Briest W, Zimmer HG, (2002) Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 55: 329-40.
40. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355: 1126-1130.
41. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, et al. (2005) Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 23: 1083-1090.
42. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. (2001) Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 38: 2132-2133.
43. Mayosi BM, Keavney B, Kardos A, Davies CH, Ratcliffe PJ, et al. (2002) Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur Heart J 23: 1963-1971.